EUCTR2019-002704-41-EE进行中（未招募）1 期
A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with partial response to SSRI treatment
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
- •- The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score =24 at screening and baseline.
- •- The patient has had the current MDE for =3 months and < 12 months.
- •- The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE and with a partial response and is a candidate for a switch in the investigator’s opinion.
- •- The patient wants to switch antidepressant treatment.
- •Other inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.
- •Other exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression ( VIVRE )EUCTR2019-002704-41-ESH. Lundbeck A/S600
进行中（未招募）
1 期
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression ( VIVRE )EUCTR2019-002704-41-CZH. Lundbeck A/S600
进行中（未招募）
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.EUCTR2011-002362-21-ESH. Lundbeck A/S500
进行中（未招募）
1 期
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.-Major Depressive Disorder (MDD)MedDRA version: 14.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-002362-21-BEH. Lundbeck A/S500
进行中（未招募）
不适用
A study of the new pharmaceutical LuAA21004 in comparison to agomelatine in adults suffering from major depression who did not respond well to previous medication.-Major Depressive Disorder (MDD)MedDRA version: 14.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-002362-21-EEH. Lundbeck A/S500